Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Leases (2020 - 2025)

Revolution Medicines has reported Current Leases over the past 6 years, most recently at $16.5 million for Q4 2025.

  • Quarterly results put Current Leases at $16.5 million for Q4 2025, up 27.94% from a year ago — trailing twelve months through Dec 2025 was $16.5 million (up 27.94% YoY), and the annual figure for FY2025 was $16.5 million, up 27.94%.
  • Current Leases for Q4 2025 was $16.5 million at Revolution Medicines, up from $16.3 million in the prior quarter.
  • Over the last five years, Current Leases for RVMD hit a ceiling of $16.5 million in Q4 2025 and a floor of $3.7 million in Q1 2021.
  • Median Current Leases over the past 5 years was $6.9 million (2022), compared with a mean of $8.4 million.
  • Biggest five-year swings in Current Leases: decreased 17.98% in 2023 and later surged 94.45% in 2025.
  • Revolution Medicines' Current Leases stood at $6.2 million in 2021, then rose by 9.0% to $6.8 million in 2022, then increased by 8.8% to $7.4 million in 2023, then surged by 74.68% to $12.9 million in 2024, then increased by 27.94% to $16.5 million in 2025.
  • The last three reported values for Current Leases were $16.5 million (Q4 2025), $16.3 million (Q3 2025), and $13.1 million (Q2 2025) per Business Quant data.